参考文献/References:
[1]Yu Z,Guo X,Jiang Y,et al.Adjuvant endocrine monotherapy for postmenopausal early breast cancer patients with hormone-receptor positive:a systemic review and network meta-analysis[J].Breast Cancer,2017,25(1):8-16.
[2]李焰,蒲玉平,郑轲,等.化疗对乳腺癌患者激素水平及月经状态的影响[J].现代生物医学进展,2018,18(12):157-160,174.
[3]黄兵江,樊涛,郑静,等.绝经前乳腺癌治疗手段与闭经相关性的研究进展[J].实用医学杂志,2018,34(2):331-334.
[4]Gradishar WJ,Anderson BO,Balassanian R,et al.Invasive Breast Cancer Version1.2016,NCCN Clinical Practice Guidelines in Oncology[J].Journal of the National Comprehensive Cancer Network,2016,14(3):324.
[5]中国抗癌协会乳腺癌专业委员会.中国绝经前女性乳腺癌患者辅助治疗后绝经判断标准及芳香化酶抑制剂临床应用共识[J].中国癌症杂志,2012,22(3):321-323.
[6]中国抗癌协会乳腺癌专业委员会.中国早期乳腺癌卵巢功能抑制临床应用专家共识(2018年版)[J].中国癌症杂志,2018,28(11):76-85.
[7]中国抗癌协会乳腺癌专业委员会.中国抗癌协会乳腺癌诊治指南与规范(2015版)[J].中国癌症杂志,2015,25(9):692-753.
[8]杨慧芬,罗华,杨欧欧,等.绝经前Luminal型乳腺癌患者血清生殖激素水平与内分泌治疗后血管舒缩功能障碍的相关性研究[J].浙江创伤外科,2016(1):1-4.
[9]王华龙,王鸿波,单世胜,等.阿那曲唑和他莫昔芬对绝经后乳腺癌患者子宫内膜、血脂代谢、免疫功能和性激素的影响[J].解放军医药杂志,2018,30(5):40-43.
[10]杨新明,吴绍洋,陈莉丽,等.三苯氧胺对乳腺癌围绝经期患者性激素水平的影响[J].中国医药导报,2011,8(30):74-75.
[11]Madeddu C,Gramignano G,Kotsonis P,et al.Ovarian hyperstimulation in premenopausal women during adjuvant tamoxifen treatment for endocrine-dependent breast cancer:A report of two cases[J].Oncology Letters,2014,8(3):1279-1282.
[12]闫莉.方玄驹胶囊联合他莫昔芬对多囊卵巢综合征不孕患者性激素水平变化及妊娠率的影响[J].中国民间疗法,2019,27(4):71-73.
[13]王健,赵冬梅,范宇.乳腺癌患者长期口服三苯氧胺对激素水平影响[J].中国实用医药,2013,8(31):239-240.
相似文献/References:
[1]董 云.SPECT/CT 双时相99mTc- MIBI断层显像
在乳腺癌诊断中的应用[J].医学信息,2018,(05):147.[doi:10.3969/j.issn.1006-1959.2018.05.053]
DONG Yun.Application of SPECT/CT Dual-phase 99mTc-MIBI Tomography in the Diagnosis of Breast Cancer[J].Medical Information,2018,(20):147.[doi:10.3969/j.issn.1006-1959.2018.05.053]
[2]于 东.平消片为主组合方案治疗乳腺增生症临床分析[J].医学信息,2018,(08):136.[doi:10.3969/j.issn.1006-1959.2018.08.046]
YU Dong.Clinical Analysis of the Combination of Pingxiao Tablets in the Treatment of Mammary Hyperplasia[J].Medical Information,2018,(20):136.[doi:10.3969/j.issn.1006-1959.2018.08.046]
[3]李建辉,祝旭龙.乳腺癌的治疗管理——把好生活质量关[J].医学信息,2018,(13):1.[doi:10.3969/j.issn.1006-1959.2018.13.001]
[4]杨玉峰,李 强,曲国红,等.乳腺癌术前巴德枪穿刺检测ER、PR的临床研究[J].医学信息,2018,(13):163.[doi:10.3969/j.issn.1006-1959.2018.13.050]
YANG Yu-feng,LI Qiang,QU Guo-hong,et al.Clinical Study on Preoperative ER and PR Detection of Bard Gun Puncture in Breast Cancer[J].Medical Information,2018,(20):163.[doi:10.3969/j.issn.1006-1959.2018.13.050]
[5]刘 曼,厉玛倩倩,徐润润,等.延续性护理对乳腺癌术后化疗患者生活质量与
健康知识水平的影响[J].医学信息,2018,(16):178.[doi:10.3969/j.issn.1006-1959.2018.16.057]
LIU Man,LIMA Qian-qian,XU Run-run,et al.Effect of Continuous Nursing on Quality of Life and Health Knowledge of Postoperative Chemotherapy Patients with Breast Cancer[J].Medical Information,2018,(20):178.[doi:10.3969/j.issn.1006-1959.2018.16.057]
[6]张艳萍,曹 玉,孙国平.服用阿司匹林对乳腺癌患者生存获益的Meta分析[J].医学信息,2018,(20):72.[doi:10.3969/j.issn.1006-1959.2018.20.021]
ZHANG Yan-ping,CAO Yu,SUN Guo-ping.Meta Analysis of the Survival Benefit of Patients with Breast Cancer Treated with Aspirin[J].Medical Information,2018,(20):72.[doi:10.3969/j.issn.1006-1959.2018.20.021]
[7]钟 磊,谢海燕,林 霖.电化学发光免疫分析技术检测肿瘤标志物在乳腺癌诊断中的应用[J].医学信息,2018,(20):155.[doi:10.3969/j.issn.1006-1959.2018.20.048]
ZHONG Lei,XIE Hai-yan,LIN Lin.Application of Electrochemiluminescence Immunoassay for Detection of Tumor Markers in Diagnosis of Breast Cancer[J].Medical Information,2018,(20):155.[doi:10.3969/j.issn.1006-1959.2018.20.048]
[8]胡平华,黄 勤,李志华.含卡培他滨方案一线或后线治疗晚期乳腺癌的效果对比[J].医学信息,2018,(22):142.[doi:10.3969/j.issn.1006-1959.2018.22.041]
HU Ping-hua,HUANG Qin,LI Zhi-hua.Comparison of the Efficacy of Capecitabine Regimen in the Treatment of Advanced Breast Cancer with First-line or Posterior Line Therapy[J].Medical Information,2018,(20):142.[doi:10.3969/j.issn.1006-1959.2018.22.041]
[9]阙海涛,曹 斌,秦志刚.EGFL7在乳腺癌中的研究进展[J].医学信息,2018,(23):32.[doi:10.3969/j.issn.1006-1959.2018.23.010]
QUE Hai-tao,CAO Bin,QIN Zhi-gang.Research Progress of EGFL7 in Breast Cancer[J].Medical Information,2018,(20):32.[doi:10.3969/j.issn.1006-1959.2018.23.010]
[10]张文婧,宋 冰.HER-2阳性乳腺癌分子靶向治疗进展[J].医学信息,2018,(24):42.[doi:10.3969/j.issn.1006-1959.2018.24.012]
ZHANG Wen-jing,SONG Bing.Progress in Molecular Targeted Therapy for HER-2 Positive Breast Cancer[J].Medical Information,2018,(20):42.[doi:10.3969/j.issn.1006-1959.2018.24.012]